IntrOduCtIOn
The management of rheumatoid arthritis (RA) has changed dramatically over the last 20 years thanks to early intensive treatment and the availability of new drugs. In order to assess disease activity, the European League Against Rheumatism (EULAR) recommends ultrasonography (US) for both assessing inflammatory activity and evaluating patients in remission as it can detect inflammation predicting subsequent joint damage. 1 On the other hand, the more recent EULAR recommendations for the management of RA 2 state that Boolean and index-based (Simplified Disease Activity Index-SDAI and Clinical Disease Activity Index-CDAI) definitions of clinical remission should be used for defining disease activity and remission. Further, two recent studies that compared targeting US remission with targeting clinical remission or low disease activity demonstrated no advantages of targeted US remission. 3 4 However, such strategic trials in patients in clinical remission are lacking and there is no recommendation on the use of imaging in patients achieving clinical remission.
Musculoskeletal ultrasound (MSUS) can provide diagnostic and prognostic data in terms of risk of flare, disability and damage progression in RA. [5] [6] [7] [8] Furthermore, MSUS allows the assessment of periarticular structures such as tendons, which could present inflammatory changes also in clinical remission. 9 In particular, the prognostic value of US tendon inflammation in patients in clinical remission is not known. 
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On this basis, the MSUS Study Group of the Italian Society for Rheumatology prioritised its research activities on defining the role of US for the assessment of patients with RA in clinical remission, launching the Sonographic Tenosynovitis/arthritis Assessment in Rheumatoid Arthritis Patients in Remission (STARTER) study. The main objective of this study is to determine the prevalence of US tenosynovitis in patients with RA in clinical remission and its association with unstable remission, function and damage. The secondary aim of the study is to assess the prevalence of joint synovitis and its association with flare, function and damage.
MetHOds

Patient and study design
This is a longitudinal analysis of the STARTER study, including 25 rheumatology centres. Selection criteria are fully described elsewhere. 10 ACR/EULAR Boolean definition, 16 the absence of swollen/tender joints on 28 joints 17 or remission based on clinical evaluation of an expert rheumatologist. 18 For the present analyses, patients with a baseline DAS28 <3.2 were included. A secondary analysis in patients with DAS28 <2.6 was performed for the primary outcome and the functional outcome.
Written informed consent was obtained.
Clinical assessment
A full description of the clinical assessment is reported in the online supplementary file S1. Demographic (age and sex) and clinical variables (disease and remission duration and treatment), rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) were recorded at baseline. Clinimetric measures (the Italian version of the Health Assessment Questionnaire (HAQ), 19 Visual Analogue Scale for pain, physician global assessment, patient global assessment and global health), erythrocyte sedimentation rate, C reactive protein and 28-joint count were collected at baseline, 6 and 12 months by a rheumatologist blinded to US findings and before the US examination. Treatment (including disease-modifying antirheumatic drugs (DMARDs), biologics, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs)) could be modified by discretion of the treating physician. Hands, wrists and feet plain radiographs were collected at baseline and 12 months. The Sharp van Der Hejide Score (erosion, joint space narrowing (JSN) and total score) was measured in pairs of radiographs by two external assessors blinded to clinical and US findings.
Outcome measures
Disease flare, defined as change in DAS28 ≥1.2 or ≥0.6 if final DAS28 >3. 2, 20 was the primary outcome. An alternative definition of flare, defined as the intention of the treating physician to increase therapy, was also recorded. Secondary outcomes included a change in the HAQ≥0.23 21 and the change in the Sharp van Der Hejide Score (SHS) (total (Δ >4.3), erosion (Δ ≥3) and JSN (Δ ≥2)). 22 For all outcomes, US variables were measured at baseline and outcomes were evaluated at 12 months. A secondary analysis evaluated the impact of baseline US on flare at 6 months and the impact of 6 months US on flare at 12 months, including dichotomous variables in the model for treatment decrease (defined as dose reduction or withdrawals of DMARDs, biologics or corticosteroids, including dose modification related to adverse events) and for treatment increase (defined as dose increase or introduction of a new drug). Further, to test the solidity of our results, the main analysis was repeated introducing the centre as a random effect. Finally, an exploratory analysis of patients fulfilling the SDAI definition of remission (≤3.3) for the primary outcome (flare defined based on the change of DAS28) was performed.
ultrasonographic assessment
Ultrasonographers were rheumatologists expert in MSUS selected by an inter-observer and intra-observer reliability exercise against a reference standard (AI) on static images using an e-learning platform. A good to excellent reliability (weighted kappa ≥0.7) 23 was required. Centres providing high level US machines (MyLab 70XVG, MyLab Twice, Logiq9, LogiqE9) with high frequency probes (14-18 MHz) were included (online supplementary file S1). MSUS following the EULAR guidelines 24 was performed by a single ultrasonographer blinded to clinical data at the baseline, 6 and 12 months.
A detailed description of the scanning protocol has been published previously. 10 The flexors of the fingers, the flexor carpi radialis and the extensor tendons of the wrist were scanned bilaterally. The dorsal aspects of wrists (radiocarpal and midcarpal joints), metacarpophalangeal joints and the palmar aspects of proximal interphalangeal joints were scanned bilaterally.
Tenosynovitis, joint effusion and synovial hypertrophy were identified according to Outcome Measures in Rheumatology Clinical Trials definitions. 25 Power Doppler (PD) assessment was performed under standardised settings. 10 Representative images were recorded.
Grey scale (GS) and PD tenosynovitis (T) and synovitis (S) were semiquantitatively scored from 0 to 3. Total scores for GS and PD T and S were obtained as the sum of single sites. An image atlas with examples of the scoring was distributed to the sonographers. 10 T and S were treated as categorical variables, defining their presence in case of GS or PD ≥1. To test the solidity of our results, alternative definitions were tested (GS >1, PD >1 for T and S).
statistical analysis
The minimal sample size to detect an OR of 1.91 for the primary outcome was defined as 250 subjects. Analyses were performed on complete data. Missing data were handled using available case analysis; in each analysis, all cases with available data on the relevant variables were included. Descriptive statistics were performed for demographic, clinical and US variables, reporting results as percentages, mean with SD or median and IQRs. Patients presenting a flare in the first 6 months were compared with patients with a flare in the second 6 months by Wilcoxon signed-rank test or Pearson's χ 2 test. The association between US variables and the outcomes was evaluated through logistic regression and the results were presented as OR and 95% CI, both crude and adjusted for prespecified confounders: age, sex, disease duration, remission duration, musculoskeletal comorbidities, RF, ACPA, DMARDs, biologics, NSAIDs, systemic glucocorticoids and local injected glucocorticoids. To fully evaluate the predictive role of US variables, time-to-event analyses using Cox proportional hazard models were also performed, using the same confounders.
To evaluate the additional impact of US and clinimetric variables on top of clinical findings, a model predicting the risk of flare, including age, gender, disease duration, musculoskeletal comorbidities, RF and ACPA, remission duration, DMARDs, biologics, steroid injections and NSAIDs, was created, presenting the results as area under the curve (AUC) with 95% CI. Each single variable was added to the null model. Since some of the clinimetric variables are included in DAS28 and relate directly to the outcome, flare also defined as intention to change treatment was tested; this definition was correlated with DAS28-defined flare by Pearson's correlation coefficient.
Data were collected and managed using Research Electronic Data Capture (REDCap). 26 Analyses were performed using STATA software package (2009, release 11; StataCorp, Texas, USA) and R statistical software (Foundation for Statistical Computing, Vienna, Austria).
results demographic and clinical characteristics
A total of 361 patients were included, with a mean (SD) age of 56.19 (13.31) years, and 261/361 (72.3%) were women, with a mean (SD) disease duration of 9.75 (8.07) years. Patients who satisfied any remission criteria but had a DAS28>3.2 at the time of enrolment were included for the cross-sectional analysis (66 patients) that has been published previously 10 but excluded from the longitudinal one as they had a partial overlap with the primary outcome. The 283 patients with DAS28 <2.6 had a mean (SD) age of 55.85 (13.55) years and 202/283 (71.3%) were women. Clinical and demographic features of both populations are presented in online supplementary file S2, while treatment patterns are displayed in online supplementary file S3. After 6 months, 344 patients were still followed, while at 12 months 340. The clinical and US features at each time point are shown in table 1.
Primary outcome: disease flare
In the follow-up, 98/326 (30.0%) patients presented a flare. When comparing 56 patients with a flare in the first 6 months with patients with a flare in the second 6 months (40 patients), there were no statistically significant differences in the demographic, clinical and clinimetric variables. For two patients with a flare at 12 months, the 6 months DAS28 were missing. Online supplementary file S4 reports the clinical and US variables in patients with flare at available follow-up times. In the same population, the concurrent presence of PD T and S and GS T and S predicted disease flare, with an OR (CI) of 2.75 (1.45 to 5.20) in crude analyses and 2.09 (1.06 to 4.13) in adjusted analyses for PD and of 2.88 (1.34 to 6.14) in crude models for GS, which was no longer statistically significant (2.25 (1.00 to 4.06)) when adjusted (table 2, figure 1). When applying Cox proportional hazard model, while in crude analysis PD S and the concurrent presence of PD T and S were significant predictors of flare, after adjustment only PD S predicted flare (data not shown). When adding the centre as a random effect, concurrent PD T and S were still significant predictors (OR 2.19 (CI 1.07 to 4.48)) while also concurrent GS T and S achieved statistical significance (OR 2.37 (CI 1.03 to 5.49)). To verify the effect of the inclusion of multiple confounders, we repeated the analysis keeping in the model only significant confounders. This confirmed the previous results (data not shown).
In the 182 patients with DAS28 <2.6, in which 75 flares occurred, the concurrent presence of T and S significantly predicted flare in crude models for both GS and PD (OR 2.59 (CI 1.25 to 5.35) and 2.64 (1.17 to 5.96), respectively), but statistical significance was lost after adjustment (OR 1.87 (CI 0.85 to 4.12) and 1.94 (CI 0.80 to 4.68), respectively). At baseline, 261 patients fulfilled SDAI remission, of whom 61 had a flare in the 12 months of observation. In this population, only the concurrent presence of PD positive synovitis and tenosynovitis significantly predicted flare (OR 2.32 (CI 1.01 to 5.32)) (online supplementary file S5).
secondary outcome: HAQ
In the 12 months follow-up, 70/326 (21.5%, 14 had missing data) of patients had a significant increase in the HAQ; 33/228 patients (14.5%) in the non-flare group and 35/98 (35.7%) in the flare group (p<0.001), while for 2 the information on flare was missing. In the DAS28 <2.6 cohort, 55/283 (19.4%) had a significant increase in the HAQ. In both cohorts, US variables did not significantly predict the worsening of function (online supplementary file S6).
secondary outcome: radiographic progression
For 189 of 361 patients of this longitudinal analysis, baseline and 12-month radiographs were available. At baseline, the median total SHS (IQR) was 24.52 , the median erosion score was 1 (0-5) and the JSN score was 8 . At 12 months, 39/189 patients (20.6%) had a progression in the total score, 25/189 (13.2%) in the erosion score and 71/189 (37.6%) in the JSN score. The mean (SD) change of the total SHS score was 3.1 (8.28), 1.12 (3.6) for the erosion score and 1.91 (6.84) for JSN score. In the population of patients with DAS28 <2.6 (157/361 patients with complete radiographic data), the median (IQR) baseline total SHS was 9 (2-28), while the scores for erosions and JSN were 1 (0-4) and 7 (2-23), respectively. At 12 months, 34/157 (21.7%) patients had a progression in the total SHS score, 20/157 (12.7%) in the erosion score and 59/157 (37.6%) in the JSN score. The mean (SD) change of the total SHS was 3.06 (6.42); 1.08 (3.7) and 1.98 (4.68) for the erosion and JSN scores, respectively. Patients with radiographic progression were equally distributed in the groups of patients with and without flare (12/55-21.8% and 27/130-20.8%, respectively, p=1; four patients had missing data for flare). None of the investigated US variables significantly predicted radiographic progression also when erosion and JSN scores were examined separately (online supplementary file S7).
sensitivity analysis-stringent Gs and Pd definitions
More stringent definitions for GS and PD were applied in patients with DAS28 <3.2, in which 98/326 (30.0%) flares were reported. In crude and adjusted models, concurrent GS T and S predicted flare (OR 2.9 (CI 1.2 to 7.05)). For PD, in both crude and adjusted models, only the presence of isolated S predicted flare (OR 1.98 (CI 1.02 to 3.81)). Three hundred and forty patients were available to assess HAQ progression, and 70 significantly progressed, but no US variable predicted a significant progression (online supplementary file S8). For progression of the SHS, occurring in 39/189 (20.6%) patients, while in crude analysis GS S predicted progression of the erosion score (occurring in 25/189 (13.2%) patients) and JSN score (occurring in 71/189 (37.6%) patients), this was no longer significant when adjusted. In both crude and adjusted analyses, the concurrent presence of GS T and S significantly predicted the progression of the JSN score (OR 5.28 (CI 1.26 to 22.21)) (online supplementary file S9).
risk of 6-month and 12-month flares
The risk of flare at 6 months based on baseline US and the risk of flare at 12 months based on 6 months US were calculated. In 
treatment decrease
Analyses of the risk of flare at 12 months, predicted by 6 months US variables, were repeated inserting a dichotomous variable into treatment decrease. With the addition of this variable, in adjusted models, PD S (OR 3.01 (CI 1.36 to 6.63)) and GS T+S (OR 3.86 (CI 1.31 to 11.39)) were still significant predictors of flare (online supplementary file S10).
Application of us information in a clinical context
A weak but significant correlation was found between DAS28-defined flare and the intention to change treatment (r 0.22, (table 3) .
dIsCussIOn
According to the latest EULAR recommendations, the treatment of RA should aim at clinical remission, 2 defined by clinical indices, to prevent joint damage and worsening of function. On the other hand, subclinical imaging-detected inflammation in clinical remission leads to flare and radiographic progression. 5 7 18 27 28 Further, clinical indices do not consider tendon involvement, which is frequent 29 30 and has an impact on disability. 31 Finally, the cross-sectional results of the STARTER study show the association between tenosynovitis and FLARE questionnaire in clinical remission. 10 The longitudinal analysis of the STARTER cohort confirmed that the conjunct presence of PD positive tenosynovitis and synovitis predicts disease flare. While this result emerges consistently in the overall population and in patients in remission according to SDAI, it is not confirmed when limiting the analyses to patients with DAS28 <2.6, possibly because of a smaller sample and a baseline lower risk of flare. With more stringent definitions for synovitis and tenosynovitis, a potential predictivity also emerged for GS. The conjunct effect of tenosynovitis and synovitis was not confirmed in time-to-event analysis, while synovitis was still a significant predictor of flare, suggesting in this case a more prominent role of synovitis. This is the first description of the impact of US-detected tenosynovitis in RA in clinical remission, highlighting a gap in the evaluation of disease activity, which is limited to joints. Taking also tenosynovitis into account could better drive therapeutic decisions, since the impact seems to be more relevant in patients in which treatment is tapered. In addition, patients with positive PD have a higher risk of flare and should be monitored more tightly. This result was achieved defining clinical remission heterogeneously, in a multicentre study, using different US machines with different operators. While this might be regarded as a limitation, it probably implies a larger generalisability of the result, which is more likely to be reproduced in a clinical setting.
Regarding the secondary outcomes, US tenosynovitis or synovitis did not show any correlation with function worsening defined by the HAQ. This could be expected, as the sample size was powered to detect the primary outcome. The detection of a difference in patients who are not likely to progress Flare occurred in 56 patients in the first semester and in 40 patients in the second one. Baseline US over the risk of flare at 6 months and 6 months US over the risk of flare at 12 months. Analyses adjusted for age, gender, disease duration, musculoskeletal comorbidities, rheumatoid factor positivity +ACPA, remission duration, the use of synthetic diseasemodifying antirheumatic drugs, biological disease -modifying antirheumatic drugs, corticosteroids or non-steroidal anti-inflammatory drugs. DAS28, Disease Activity Score on 28 joints; GS, grey scale; PD, power Doppler; S, synovitis; T, tenosynovitis; US, ultrasonography. The null model includes age, gender, disease duration, musculoskeletal comorbidities, rheumatoid factor and anti-cyclic citrullinated peptides, remission duration, disease-modifying antirheumatic drugs, biological disease-modifying antirheumatic drugs, steroid injections and non-steroidal anti-inflammatory drugs. AUC, area under the curve; DAS28, Disease Activity Score on 28 joints; EGA, evaluator's global assessment; GH, general health; GS, grey scale; PD, power Doppler; PGA, patient global assessment; S, synovitis; SJC, swollen joint count; T, tenosynovitis; TJC, tender joint count; US, ultrasonography; VAS, Visual Analogue Scale.
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rapidly would have required a larger sample as well as a longer follow-up. The same considerations can be applied to the radiographic outcome, whose relevance has been questioned very recently, 32 33 based on the reduction of its occurrence 34 and our population is not an exception.
Regarding the timing of US, in our study, US predicts flare at 12 months but not at 6. This suggests that in patients without any US inflammation, it could be useful to repeat US yearly.
The addition of US and clinimetric variables to a model predicting flare did not lead to a relevant improvement of its performance. Neither swollen nor tender joint counts improved the prediction, and both counts, as well as acute phase reactants, remained substantially unchanged at flare, while greater changes were seen in patient's reported outcomes. This aspect raises a further very important question: are the actual clinical indices adequate for defining remission and flare in all patients? In many of our patients, US did not reveal inflammatory exacerbation and flare was mainly PRO driven. It looks like the hot soup paradox of the Italian tradition: 'who was burn with the soup blows also on the water?'
The need for composite disease activity indexes emerged in the 1990s and in a short period different indexes appeared. 15 35 All were meant to assess active disease but later emerged as a milestone in management. 2 Their thresholds for defining remission have been established 16 in randomised clinical trials and even in this context, almost 10% of patients in DAS28 remission had EGA and PGA scores compatible with active disease. In our cohort, comorbidities (with 20% of patients with osteoarthritis and 2% with fibromyalgia) could have interfered with the patient and physician's reported outcomes, shifting patients from stable to unstable remission.
US has demonstrated to be very sensitive in RA and its value has been acknowledged in the EULAR recommendations. 1 However, recent studies questioned the added value of US in guiding therapeutic decision, 3 4 since US did not demonstrate to improve the outcomes, despite some possible methodological limitations. 36 Further, the role of residual US-detectable inflammation in clinical remission is still not clearly defined, considering that inflammatory changes can also be found in healthy subjects. 37 The STARTER study demonstrated that tendon and joint US can be useful in assessing inflammatory changes in RA in clinical remission to predict disease outcome and the impact of these findings on disease management should be tested in strategic trials.
On the other hand, in this cohort, disease flare is not always accompanied by a clinical and laboratory worsening but mainly by a change in the PROs, which might be influenced by comorbidities. In this scenario, US could confirm active disease and drive the therapeutic decision on top of composite indexes, in accordance with a recent proposal by a group of US experts. 38 The research agenda on US in patients with RA in clinical remission is rich in unanswered questions regarding both the impact of PROs and the role of US. Decision making in RA should not be based on a single parameter and should be taken after acquisition of as much data as possible regarding the sensations of the patient and objective and reliable data on disease activity. This is a doctor's job, not a machine's or a number's. . Analyses were performed on 326 patients; 98 flares occurred during observation and were adjusted for age, gender, disease duration, musculoskeletal comorbidities, rheumatoid factor and ACPA positivity, remission duration, the use of synthetic disease -modifying antirheumatic drugs, biological disease -modifying antirheumatic drugs, corticosteroids or non-steroidal anti-inflammatory drugs. DAS28, Disease Activity Score on 28 joints; GS, grey scale; PD , power Doppler; S, synovitis; T, tenosynovitis.
